Sommerfeld H J, Meeker A K, Piatyszek M A, Bova G S, Shay J W, Coffey D S
Kath. Marienhospital II, Urologische Klinik, Ruhr Universitat Bochum, Herne, Germany.
Cancer Res. 1996 Jan 1;56(1):218-22.
We urgently need biochemical markers to detect the malignant nature and pathological states of the human prostate. We report that telomerase activity is associated with prostate cancer but absent in the benign disease and normal gland. Telomerase is, therefore, a potential diagnostic marker for prostate cancer. Twenty-five human prostates resected at the time of radical prostatectomy were dissected to obtain matched adjacent areas of normal, central zone benign prostatic hyperplasia (BPH), and pathologically confirmed cancer tissue. These matched tissue samples were assayed for telomerase activity using a sensitive PCR technique. None of the normal tissues exhibited telomerase activity. In contrast, 21 of the 25 (84%) cancers were strongly positive. At the time of prostatectomy, four lymph nodes were positive for metastases and all were strongly positive for telomerase activity. In adjacent BPH tissues taken from the cancerous prostates, only 3 of the 25 tissues (12%) were weakly positive. Telomerase activity was not detected in ten BPH samples recovered from patients who underwent open surgery solely for BPH. All five available cell lines of human prostate cancer (DU145, LNCaP, PC3, PPC1, and TSU) were strongly positive. Short telomere lengths have been observed in several human cancers. We also measured the telomere lengths in 27 matched samples of normal, BPH, and cancer tissue taken from nine radical prostatectomies. The telomeres from cancer tissue were significantly and consistently shorter than either the adjacent normal or adjacent BPH tissues. Our results indicate that telomerase activity, as well as telomere lengths, may be markers for distinguishing prostate cancer from normal and benign prostate tissues.
我们迫切需要生物化学标志物来检测人类前列腺的恶性性质和病理状态。我们报告端粒酶活性与前列腺癌相关，但在良性疾病和正常腺体中不存在。因此，端粒酶是前列腺癌的一种潜在诊断标志物。在根治性前列腺切除术时切除的25个人类前列腺被解剖，以获取正常、中央区良性前列腺增生（BPH）和病理确诊的癌组织的匹配相邻区域。使用灵敏的PCR技术对这些匹配的组织样本进行端粒酶活性检测。所有正常组织均未表现出端粒酶活性。相比之下，25个癌症样本中有21个（84%）呈强阳性。在前列腺切除术时，4个淋巴结有转移阳性，且所有淋巴结端粒酶活性均为强阳性。在取自癌性前列腺的相邻BPH组织中，25个组织中只有3个（12%）呈弱阳性。在仅因BPH接受开放手术的患者中回收的10个BPH样本中未检测到端粒酶活性。所有5种可用的人类前列腺癌细胞系（DU145、LNCaP、PC3、PPC1和TSU）均呈强阳性。在几种人类癌症中观察到短端粒长度。我们还测量了取自9例根治性前列腺切除术的27个正常、BPH和癌组织匹配样本中的端粒长度。癌组织的端粒明显且始终比相邻的正常或相邻BPH组织短。我们的结果表明，端粒酶活性以及端粒长度可能是区分前列腺癌与正常和良性前列腺组织的标志物。
